

Timothy D Henry Mscai

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7718539/publications.pdf>

Version: 2024-02-01

250
papers

13,875
citations

34016

52
h-index

22764

112
g-index

257
all docs

257
docs citations

257
times ranked

13505
citing authors

#	ARTICLE	IF	CITATIONS
1	Variability in reporting of key outcome predictors in acute myocardial infarction cardiogenic shock trials. Catheterization and Cardiovascular Interventions, 2022, 99, 19-26.	0.7	21
2	Laboratory Markers of Acidosis and Mortality in Cardiogenic Shock: Developing a Definition of Hemometabolic Shock. Shock, 2022, 57, 31-40.	1.0	27
3	Influence of intra-aortic balloon pump on mortality as a function of cardiogenic shock severity. Catheterization and Cardiovascular Interventions, 2022, 99, 293-304.	0.7	14
4	Recommendations for nomenclature and definition of cell products intended for human cardiovascular use. Cardiovascular Research, 2022, 118, 2428-2436.	1.8	6
5	The direct and indirect effects of the COVID-19 pandemic on cardiovascular disease throughout the world. European Heart Journal, 2022, 43, 1154-1156.	1.0	11
6	Autologous CD34+ Stem Cell Therapy Increases Coronary Flow Reserve and Reduces Angina in Patients With Coronary Microvascular Dysfunction. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121010802.	1.4	16
7	The impact of regional STEMI systems on protocol use and quality improvement initiatives in community hospitals without cardiac catheterization laboratories. American Heart Journal Plus, 2022, 13, 100077.	0.3	0
8	The Dawn of a New Era. , 2022, 1, 100010.		0
9	SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies. Journal of the American College of Cardiology, 2022, 79, 933-946.	1.2	214
10	Coding the COVID patient: Is it futile?. Catheterization and Cardiovascular Interventions, 2022, 99, 9-10.	0.7	2
11	SCAI SHOCK Stage Classification Expert Consensus Update: A Review and Incorporation of Validation Studies. , 2022, 1, 100008.		8
12	Management Principles for the Cardiac Catheterization Laboratory During the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Pandemic. Interventional Cardiology Clinics, 2022, 11, 325-338.	0.2	1
13	Impact of COVID-19 on Acute Myocardial Infarction Care. Cardiology Clinics, 2022, 40, 345-353.	0.9	7
14	Mechanical Circulatory Support in COVID-19. Cardiology Clinics, 2022, , .	0.9	3
15	Cardiac Registries During the COVID-19 Pandemic: Lessons Learned. Current Cardiology Reports, 2022, , 1.	1.3	2
16	The 2021 AHA/ACC Guideline for the Evaluation and Diagnosis of Chest Pain: An Interventionalist's Viewpoint. , 2022, , 100305.		1
17	STEMI: Considerations for Left Main Culprit Lesions. Current Cardiology Reports, 2022, , 1.	1.3	3
18	Trends in Clinical Presentation, Management, and Outcomes of STEMI in Patients With COVID-19. Journal of the American College of Cardiology, 2022, 79, 2236-2244.	1.2	18

#	ARTICLE	IF	CITATIONS
19	The Ongoing National Medical Staffing Crisis: Impacts on Care Delivery for Interventional Cardiologists. , 2022, , 100307.		3
20	Better early than later!. Catheterization and Cardiovascular Interventions, 2022, 99, 1509-1510.	0.7	0
21	Contemporary Management of Refractory Angina. Interventional Cardiology Clinics, 2022, 11, 279-292.	0.2	1
22	North American COVID-19 Myocardial Infarction (NACMI) Risk Score for Prediction of In-Hospital Mortality. , 2022, , 100404.		5
23	Impact of COVID-19 pandemic on STEMI care: An expanded analysis from the United States. Catheterization and Cardiovascular Interventions, 2021, 98, 217-222.	0.7	70
24	Temporal changes in patient characteristics and outcomes in ST-segment elevation myocardial infarction 2003-2018. Catheterization and Cardiovascular Interventions, 2021, 97, 1109-1117.	0.7	18
25	Adapting STEMI care for the COVID-19 pandemic: The case for low-risk STEMI triage and early discharge. Catheterization and Cardiovascular Interventions, 2021, 97, 847-849.	0.7	10
26	A novel method to interpret early phase trials shows how the narrowing of the coronary sinus concordantly improves symptoms, functional status and quality of life in refractory angina. Heart, 2021, 107, 41-46.	1.2	3
27	The Midwest ST-Elevation Myocardial Infarction Consortium: Design and Rationale. Cardiovascular Revascularization Medicine, 2021, 23, 86-90.	0.3	12
28	Spontaneous coronary artery dissection with cardiogenic shock: How frequent is it? How should we treat it?. Catheterization and Cardiovascular Interventions, 2021, 97, 78-79.	0.7	1
29	Defining Shock and Preshock for Mortality Risk Stratification in Cardiac Intensive Care Unit Patients. Circulation: Heart Failure, 2021, 14, e007678.	1.6	38
30	Value of Registries in ST-segment Elevation Myocardial Infarction Care in Both the Pre-Coronavirus Disease 2019 and the Coronavirus Disease 2019 Eras. Journal of the American Heart Association, 2021, 10, e019958.	1.6	5
31	Therapeutic Approaches for the No-Option Refractory Angina Patient. Circulation: Cardiovascular Interventions, 2021, 14, e009002.	1.4	16
32	Risk stratifying patients with out-of-hospital cardiac arrest: The case for dynamic predictions models. Catheterization and Cardiovascular Interventions, 2021, 97, 235-236.	0.7	0
33	Stent Thrombosis Risk Over Time on the Basis of Clinical Presentation and Platelet Reactivity. JACC: Cardiovascular Interventions, 2021, 14, 417-427.	1.1	19
34	Reliability and Validity of Current Approaches to Identification of Patients with ST-Segment-Elevation Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e007228.	0.9	2
35	The hidden costs of national lockdowns. Lancet Regional Health - Europe, The, 2021, 2, 100035.	3.0	2
36	Reparative cell therapy for the heart: critical internal appraisal of the field in response to recent controversies. ESC Heart Failure, 2021, 8, 2306-2309.	1.4	13

#	ARTICLE	IF	CITATIONS
37	New generation drug eluting stents: Closing the gap in sex disparity in cardiovascular outcomes in women. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 97, 805-806.	0.7	0
38	A Phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCRN CONCERTA-HF trial. <i>European Journal of Heart Failure</i> , 2021, 23, 661-674.	2.9	89
39	Initial Findings From the North American COVID-19 Myocardial Infarction Registry. <i>Journal of the American College of Cardiology</i> , 2021, 77, 1994-2003.	1.2	96
40	Artificial Intelligence Can Improve Patient Management at the Time of a Pandemic: The Role of Voice Technology. <i>Journal of Medical Internet Research</i> , 2021, 23, e22959.	2.1	27
41	Angiogenic CD34 Stem Cell Therapy in Coronary Microvascular Repair—A Systematic Review. <i>Cells</i> , 2021, 10, 1137.	1.8	12
42	Resilience in the Face of Adversity. <i>Journal of the American College of Cardiology</i> , 2021, 77, 2477-2479.	1.2	1
43	Cardiology Research Internship for Undergraduate Students Provides Unique Opportunity for Next Generation of Health Care Professionals. <i>JACC: Case Reports</i> , 2021, 3, 985-988.	0.3	1
44	STEMI care 2021: Addressing the knowledge gaps. <i>American Heart Journal Plus</i> , 2021, 11, 100044.	0.3	6
45	Hot topics in interventional cardiology: Proceedings from the society for cardiovascular angiography and interventions (SCAI) 2021 think tank. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 904-913.	0.7	3
46	Percutaneous coronary intervention in end-stage kidney disease: Trapped between a rock and a hard place. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 215-216.	0.7	0
47	Machine learning for holistic visualization of STEMI registry data. <i>Journal of Biomedical Informatics</i> , 2021, 121, 103869.	2.5	2
48	The first cut is the deepest (and perhaps the most opportune)!. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 481-482.	0.7	0
49	Acute Carbon Monoxide Poisoning and Cardiac Magnetic Resonance. <i>JACC: Cardiovascular Imaging</i> , 2021, 14, 1771-1773.	2.3	2
50	Functional coronary angiography for coronary microvascular function: the time has come!. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 836-837.	0.7	0
51	Frequency, Etiology, and Impact of Unplanned Repeat Coronary Angiography After ST-Elevation Myocardial Infarction. <i>American Journal of Cardiology</i> , 2021, , .	0.7	0
52	Incidence and Long-Term Outcomes of Stroke in Patients Presenting With ST-Segment Elevation Myocardial Infarction: Insights From the Midwest STEMI Consortium. <i>Journal of the American Heart Association</i> , 2021, 10, e022489.	1.6	2
53	STEMI in 90-year-olds: The good news and the bad news!. <i>Catheterization and Cardiovascular Interventions</i> , 2021, 98, 647-648.	0.7	0
54	Incidence, predictors and impact of stroke on mortality among patients with acute coronary syndromes following percutaneous coronary intervention—Results from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 95, 885-892.	0.7	5

#	ARTICLE	IF	CITATIONS
55	Impact of high on-treatment platelet reactivity on outcomes following PCI in patients on hemodialysis: An ADAPT-DES substudy. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 793-801.	0.7	6
56	Clinical and regulatory landscape for cardiogenic shock: A report from the Cardiac Safety Research Consortium ThinkTank on cardiogenic shock. <i>American Heart Journal</i> , 2020, 219, 1-8.	1.2	27
57	Coexistence of acute takotsubo syndrome and acute coronary syndrome. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 825-829.	0.7	6
58	Response: How common is comorbid takotsubo syndrome in patients with acute coronary syndromes?. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 727-727.	0.7	3
59	Admission Society for Cardiovascular Angiography and Intervention shock stage stratifies post-discharge mortality risk in cardiac intensive care unit patients. <i>American Heart Journal</i> , 2020, 219, 37-46.	1.2	48
60	Refractory Angina. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1-19.	1.1	49
61	A CHIP fellow's transition into practice: Building a complex coronary therapeutics program. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1058-1064.	0.7	8
62	“Back to the Future” for STEMI?. <i>JACC: Case Reports</i> , 2020, 2, 1651-1653.	0.3	9
63	Coronary Vascular Function and Cardiomyocyte Injury. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2020, 40, 3015-3021.	1.1	10
64	Age and shock severity predict mortality in cardiac intensive care unit patients with and without heart failure. <i>ESC Heart Failure</i> , 2020, 7, 3971-3982.	1.4	25
65	Allogeneic Mesenchymal Cell Therapy in Anthracycline-Induced Cardiomyopathy Heart Failure Patients. <i>JACC: CardioOncology</i> , 2020, 2, 581-595.	1.7	24
66	Impact of the COVID-19 pandemic on interventional cardiology training in the United States. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 997-1005.	0.7	22
67	Cardiac Imaging in the Post-ISCHEMIA Trial Era. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1815-1833.	2.3	21
68	Intracoronary ALlogeneic heart STem cells to Achieve myocardial Regeneration (ALLSTAR): a randomized, placebo-controlled, double-blinded trial. <i>European Heart Journal</i> , 2020, 41, 3451-3458.	1.0	78
69	Lessons Learned From Acute Myocardial Infarction Care in China. <i>JAMA Network Open</i> , 2020, 3, e2021768.	2.8	3
70	Cardiac procedural deferral during the coronavirus (COVID-19) pandemic. <i>Catheterization and Cardiovascular Interventions</i> , 2020, 96, 1080-1086.	0.7	22
71	Understanding How Cardiac Arrest Complicates the Analysis of Clinical Trials of Cardiogenic Shock. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006692.	0.9	47
72	Systemic Inflammatory Response Syndrome Is Associated With Increased Mortality Across the Spectrum of Shock Severity in Cardiac Intensive Care Patients. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2020, 13, e006956.	0.9	51

#	ARTICLE	IF	CITATIONS
73	Cardiac safety research consortium "shock II" think tank report: Advancing practical approaches to generating evidence for the treatment of cardiogenic shock. American Heart Journal, 2020, 230, 93-97.	1.2	14
74	STEMI in young women: Don't miss spontaneous coronary artery dissection!. Catheterization and Cardiovascular Interventions, 2020, 96, 1231-1232.	0.7	1
75	Temporary Emergency Guidance to STEMI Systems of Care During the COVID-19 Pandemic. Circulation, 2020, 142, 199-202.	1.6	28
76	Stromal Cell-Derived Factor-1 Plasmid Treatment for Patients With Peripheral Artery Disease (STOP-PAD) Trial: Six-Month Results. Journal of Endovascular Therapy, 2020, 27, 669-675.	0.8	11
77	The Robin Hood effect!. Catheterization and Cardiovascular Interventions, 2020, 95, 1109-1110.	0.7	1
78	North American COVID-19 ST-Segment-Elevation Myocardial Infarction (NACMI) registry: Rationale, design, and implications. American Heart Journal, 2020, 227, 11-18.	1.2	33
79	The Effect of Implementation of the American Heart Association Mission Lifeline PreAct Algorithm for Prehospital Cardiac Catheterization Laboratory Activation on the Rate of "False Positive" Activations. Prehospital and Disaster Medicine, 2020, 35, 388-396.	0.7	7
80	<sc>SCAI</sc> position statement on the performance of percutaneous coronary intervention in ambulatory surgical centers. Catheterization and Cardiovascular Interventions, 2020, 96, 862-870.	0.7	11
81	<sc>SCAI</sc> position statement on optimal percutaneous coronary interventional therapy for complex coronary artery disease. Catheterization and Cardiovascular Interventions, 2020, 96, 346-362.	0.7	65
82	Long-Term (3 Years) Outcomes of Ranolazine Therapy for Refractory Angina Pectoris (from the Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 38	0.7	7
83	CD34+ cell therapy significantly reduces adverse cardiac events, health care expenditures, and mortality in patients with refractory angina. Stem Cells Translational Medicine, 2020, 9, 1147-1152.	1.6	17
84	Influence of cardiac arrest and SCAI shock stage on cardiac intensive care unit mortality. Catheterization and Cardiovascular Interventions, 2020, 96, 1350-1359.	0.7	62
85	Catheterization Laboratory Considerations During the Coronavirus (COVID-19) Pandemic. Journal of the American College of Cardiology, 2020, 75, 2372-2375.	1.2	370
86	Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill. JAMA Cardiology, 2020, 5, 532.	3.0	8
87	Promise of autologous CD34+ stem/progenitor cell therapy for treatment of cardiovascular disease. Cardiovascular Research, 2020, 116, 1424-1433.	1.8	34
88	Preprocedure Thrombolysis In Myocardial Infarction (TIMI) flow grade: Has its time come and gone?. Catheterization and Cardiovascular Interventions, 2020, 95, 501-502.	0.7	4
89	Intraaortic balloon pump in myocardial infarction: Always, Never, or for the Right Patient?. Catheterization and Cardiovascular Interventions, 2020, 95, E152-E153.	0.7	0
90	Reduction in ST-Segment Elevation Cardiac Catheterization Laboratory Activations in the United States During COVID-19 Pandemic. Journal of the American College of Cardiology, 2020, 75, 2871-2872.	1.2	983

#	ARTICLE	IF	CITATIONS
91	Management of acute myocardial infarction during the COVID-19 pandemic. Catheterization and Cardiovascular Interventions, 2020, 96, 336-345.	0.7	114
92	Management of Acute Myocardial Infarction During the COVID-19 Pandemic. Journal of the American College of Cardiology, 2020, 76, 1375-1384.	1.2	335
93	Clinical Characteristics and Outcomes of STEMI Patients With Cardiogenic Shock and Cardiac Arrest. JACC: Cardiovascular Interventions, 2020, 13, 1211-1219.	1.1	56
94	Prevalence, Trends, and Outcomes of Higher-Risk Percutaneous Coronary Interventions Among Patients Without Acute Coronary Syndromes. Cardiovascular Revascularization Medicine, 2019, 20, 289-292.	0.3	9
95	Geographical Variations in Patterns of DAPT Cessation and Two-Year PCI Outcomes: Insights from the PARIS Registry. Thrombosis and Haemostasis, 2019, 119, 1704-1711.	1.8	2
96	Feasibility of a voice-enabled automated platform for medical data collection: CardioCube. International Journal of Medical Informatics, 2019, 129, 388-393.	1.6	24
97	Association Between Hypertension, Platelet Reactivity, and the Risk of Adverse Events After Percutaneous Coronary Intervention (From the ADAPT-DES Study). American Journal of Cardiology, 2019, 124, 1380-1388.	0.7	8
98	The cost of angina: how do we measure it? How do we improve it?. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 6, 5-6.	1.8	2
99	CTO PCI: When at first you don't succeed!. Catheterization and Cardiovascular Interventions, 2019, 94, 525-526.	0.7	0
100	Revascularization in Patients With Spontaneous Coronary Artery Dissection and ST-Segment Elevation Myocardial Infarction. Journal of the American College of Cardiology, 2019, 74, 1290-1300.	1.2	87
101	Cardiogenic Shock Classification to Predict Mortality in the Cardiac Intensive Care Unit. Journal of the American College of Cardiology, 2019, 74, 2117-2128.	1.2	314
102	CD34+ Cell Therapy for No-Option Refractory Disabling Angina: Time for FDA Approval?. Cardiovascular Revascularization Medicine, 2019, 20, 177-178.	0.3	9
103	A Myocardial Bridge or Not?. JAMA Cardiology, 2019, 4, 713.	3.0	0
104	SCAI clinical expert consensus statement on the classification of cardiogenic shock. Catheterization and Cardiovascular Interventions, 2019, 94, 29-37.	0.7	657
105	SDF-1 plasmid treatment for patients with peripheral artery disease (STOP-PAD): Randomized, double-blind, placebo-controlled clinical trial. Vascular Medicine, 2019, 24, 200-207.	0.8	22
106	Adverse events in patients with high platelet reactivity following successful chronic total occlusion PCI: The Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. American Heart Journal, 2019, 211, 68-76.	1.2	3
107	NHLBI-Sponsored Randomized Trial of Postconditioning During Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Circulation Research, 2019, 124, 769-778.	2.0	37
108	Biology and bias: do we have the will to improve cardiovascular disease outcomes for women?. Heart, 2019, 105, 503-505.	1.2	3

#	ARTICLE	IF	CITATIONS
109	Tailoring Antiplatelet Therapy Intensity to Ischemic and Bleeding Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2019, 12, e004945.	0.9	7
110	Patterns and Impact of Dual Antiplatelet Cessation on Cardiovascular Risk After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , 2019, 123, 709-716.	0.7	9
111	Use of prasugrel and clinical outcomes in African-American patients treated with percutaneous coronary intervention for acute coronary syndromes. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 94, 53-60.	0.7	2
112	The prevalence, predictors and outcomes of guideline-directed medical therapy in patients with acute myocardial infarction undergoing PCI, an analysis from the PROMETHEUS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E112-E119.	0.7	16
113	Incidence, predictors, management and outcomes of coronary perforations. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, 48-56.	0.7	41
114	Systematic review and directors survey of quality indicators for the cardiovascular intensive care unit. <i>International Journal of Cardiology</i> , 2018, 260, 219-225.	0.8	7
115	Value-Based ST-Segment Elevation Myocardial Infarction Care Using Risk-Guided Triage and Early Discharge. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2018, 11, e004553.	0.9	20
116	Impact of sleep deprivation on the outcomes of percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1118-1125.	0.7	4
117	The (Translational) Road Less Traveled. <i>Circulation Research</i> , 2018, 122, 207-209.	2.0	2
118	Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. <i>European Heart Journal</i> , 2018, 39, 2208-2216.	1.0	75
119	Too little, too much or just right? Goldilocks revisited. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 840-841.	0.7	0
120	Combining Stem Cell Therapy for Advanced Heart Failure and Ventricular Assist Devices: A Review. <i>ASAIO Journal</i> , 2018, 64, e80-e87.	0.9	5
121	New or presumed new left bundle branch block in patients with suspected ST-elevation myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 208-217.	0.4	12
122	Confronting system barriers for ST-elevation MI in low and middle income countries with a focus on India. <i>Indian Heart Journal</i> , 2018, 70, 185-190.	0.2	8
123	The safety and effectiveness of adenosine diphosphate receptor inhibitor pretreatment among acute myocardial infarction patients treated with percutaneous coronary intervention in community practice: insights from the TRANSLATE-ACS study. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 242-250.	0.7	4
124	TIME Trial: Effect of Timing of Stem Cell Delivery Following ST-Elevation Myocardial Infarction on the Recovery of Global and Regional Left Ventricular Function. <i>Circulation Research</i> , 2018, 122, 479-488.	2.0	50
125	Optical coherence tomography guided carotid artery stent procedure: technique and potential applications. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 91, 521-530.	0.7	18
126	Omission of heart transplant recipients from the 2017 appropriate use criteria for coronary revascularization in patients with stable ischemic heart disease. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 451-451.	0.7	0

#	ARTICLE	IF	CITATIONS
127	Prediction of Ischemic and Bleeding Events Using the Dual Antiplatelet Therapy Score in an Unrestricted Percutaneous Coronary Intervention Population. <i>Circulation: Cardiovascular Interventions</i> , 2018, 11, e006853.	1.4	17
128	Temporal Trends in the Use of Therapeutic Hypothermia for Out-of-Hospital Cardiac Arrest. <i>JAMA Network Open</i> , 2018, 1, e184511.	2.8	63
129	When small vessels become big problems! Microvascular dysfunction in NSTEMI. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1075-1076.	0.7	2
130	The Quandary of Volume! How Much Is Enough?. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 251-252.	0.7	0
131	Delays in Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients Presenting With Cardiogenic Shock. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1824-1833.	1.1	42
132	Revascularization in non-option patients with refractory angina: Frequency, etiology and outcomes. <i>Catheterization and Cardiovascular Interventions</i> , 2018, 92, 1215-1219.	0.7	13
133	Dual Antiplatelet Therapy Cessation and Adverse Events After Drug-Eluting Stent Implantation in Patients at High Risk for Atherothrombosis (from the PARIS Registry). <i>American Journal of Cardiology</i> , 2018, 122, 1638-1646.	0.7	19
134	Impact of high on-aspirin platelet reactivity on outcomes following successful percutaneous coronary intervention with drug-eluting stents. <i>American Heart Journal</i> , 2018, 205, 77-86.	1.2	6
135	Platelet Reactivity and Risk of Ischemic Stroke After Coronary Drug-Eluting Stent Implantation. <i>JACC: Cardiovascular Interventions</i> , 2018, 11, 1277-1286.	1.1	14
136	Health Status and Quality of Life of Patients Enrolled in a Specialized Refractory Angina Clinic. <i>Journal of the Minneapolis Heart Institute Foundation</i> , 2018, 2, 4-8.	0.0	2
137	The Athena trials: Autologous adipose-derived regenerative cells for refractory chronic myocardial ischemia with left ventricular dysfunction. <i>Catheterization and Cardiovascular Interventions</i> , 2017, 89, 169-177.	0.7	89
138	Association of Rapid Care Process Implementation on Reperfusion Times Across Multiple ST-Segment Elevation Myocardial Infarction Networks. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	44
139	Evaluation of Cell Therapy on Exercise Performance and Limb Perfusion in Peripheral Artery Disease. <i>Circulation</i> , 2017, 135, 1417-1428.	1.6	46
140	Use of prasugrel vs clopidogrel and outcomes in patients with acute coronary syndrome undergoing percutaneous coronary intervention in contemporary clinical practice: Results from the PROMETHEUS study. <i>American Heart Journal</i> , 2017, 188, 73-81.	1.2	25
141	Out-of-Hospital Cardiac Arrest. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 460-461.	1.1	5
142	A new 4-variable formula to differentiate normal variant ST segment elevation in V2-V4 (early) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 147 V2 improves the model. <i>Journal of Electrocardiology</i> , 2017, 50, 561-569.	0.4	29
143	Patterns and associations between DAPT cessation and 2-year clinical outcomes in left main/proximal LAD versus other PCI: Results from the Patterns of Non-Adherence to Dual Antiplatelet Therapy in Stented Patients (PARIS) registry. <i>International Journal of Cardiology</i> , 2017, 243, 132-139.	0.8	11
144	Myocardial Injury as a New Target for Cell Therapy in Patients With Chronic Heart Failure. <i>Circulation Research</i> , 2017, 120, 1857-1859.	2.0	2

#	ARTICLE	IF	CITATIONS
145	From D2B to B2D: Value based STEMI care!. Catheterization and Cardiovascular Interventions, 2017, 89, 1147-1148.	0.7	1
146	Two-year outcomes after percutaneous coronary intervention of calcified lesions with drug-eluting stents. International Journal of Cardiology, 2017, 231, 61-67.	0.8	71
147	Contemporary Management of Cardiogenic Shock: A Scientific Statement From the American Heart Association. Circulation, 2017, 136, e232-e268.	1.6	1,103
148	Sex differences in the effect of diabetes mellitus on platelet reactivity and coronary thrombosis: From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study. International Journal of Cardiology, 2017, 246, 20-25.	0.8	15
149	The importance of vision. Catheterization and Cardiovascular Interventions, 2017, 90, 10-11.	0.7	2
150	Quantifying Ischemic Risk After Percutaneous Coronary Intervention Attributable to High Platelet Reactivity on Clopidogrel (From the Assessment of Dual Antiplatelet Therapy with Drug-Eluting Stents) Tj ETQq0 0 0.784314 rgBT /Overlock 10 T	0.7	0
151	Impact of Aspirin and Clopidogrel Hyporesponsiveness in Patients Treated With Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 1607-1617.	1.1	29
152	Organizational Structure, Staffing, Resources, and Educational Initiatives in Cardiac Intensive Care Units in the United States. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, e003864.	0.9	36
153	If you prick us, do we not bleed?. Catheterization and Cardiovascular Interventions, 2017, 90, 743-744.	0.7	0
154	Sex-based differences in quality of care and outcomes in a health system using a standardized STEMI protocol. American Heart Journal, 2017, 191, 30-36.	1.2	53
155	Causes, Timing, and Impact of Dual Antiplatelet Therapy Interruption for Surgery (from the Patterns of) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T 2017, 120, 904-910.	0.7	10
156	Switching of adenosine diphosphate receptor inhibitor after hospital discharge among myocardial infarction patients: Insights from the Treatment with Adenosine Diphosphate Receptor Inhibitors: Longitudinal Assessment of Treatment Patterns and Events after Acute Coronary Syndrome (TRANSLATE-ACS) observational study. American Heart Journal, 2017, 183, 62-68.	1.2	60
157	PreSERVE-AMI. Circulation Research, 2017, 120, 324-331.	2.0	124
158	Impact of proton pump inhibitors and dual antiplatelet therapy cessation on outcomes following percutaneous coronary intervention: Results From the PARIS Registry. Catheterization and Cardiovascular Interventions, 2017, 89, E217-E225.	0.7	13
159	Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1349-1357.	1.1	54
160	Allogeneic mesenchymal precursor cells (MPCs): an innovative approach to treating advanced heart failure. Expert Opinion on Biological Therapy, 2016, 16, 1163-1169.	1.4	5
161	The Impact of Timing of Ischemic and Hemorrhagic Events on Mortality After Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2016, 9, 1450-1457.	1.1	35
162	Post <sc>PCI</sc> Angina. Catheterization and Cardiovascular Interventions, 2016, 88, 1025-1026.	0.7	0

#	ARTICLE	IF	CITATIONS
163	Despite Dramatic Progress, Significant Controversy and Critical Challenges for Patients with ST-Segment Elevation MI. <i>Interventional Cardiology Clinics</i> , 2016, 5, xiii-xiv.	0.2	0
164	Relation Between Platelet Count and Platelet Reactivity to Thrombotic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. <i>American Journal of Cardiology</i> , 2016, 117, 1703-1713.	0.7	18
165	lmyelocel-T for patients with ischaemic heart failure: a prospective randomised double-blind trial. <i>Lancet, The</i> , 2016, 387, 2412-2421.	6.3	134
166	Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents. <i>Journal of the American College of Cardiology</i> , 2016, 67, 2224-2234.	1.2	445
167	Impact of Anemia on Platelet Reactivity and Ischemic and Bleeding Risk: From the Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents Study. <i>American Journal of Cardiology</i> , 2016, 117, 1877-1883.	0.7	34
168	Response to Letter Regarding Article, "Proton Pump Inhibitors, Platelet Reactivity, and Cardiovascular Outcomes After Drug-Eluting Stents in Clopidogrel-Treated Patients: The ADAPT-DES Study," <i>Circulation: Cardiovascular Interventions</i> , 2016, 9, e003530.	1.4	0
169	Long-Term Post-Discharge Risks in Older Survivors of Myocardial Infarction With and Without Out-of-Hospital Cardiac Arrest. <i>Journal of the American College of Cardiology</i> , 2016, 67, 1981-1990.	1.2	39
170	Differences in Short- and Long-Term Outcomes Among Older Patients With ST-Elevation Versus Non-ST-Elevation Myocardial Infarction With Angiographically Proven Coronary Artery Disease. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 513-522.	0.9	42
171	The Choice Is Reperfusion Therapy. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 2021-2023.	1.1	6
172	Regional Systems of Care Demonstration Project. <i>Circulation</i> , 2016, 134, 365-374.	1.6	81
173	The RENEW Trial. <i>JACC: Cardiovascular Interventions</i> , 2016, 9, 1576-1585.	1.1	107
174	The bare naked truth! "excuse me but your metal is showing!" <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 36-37.	0.7	0
175	Design, Challenges, and Implications of Quality Improvement Projects Using the Electronic Medical Record. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2016, 9, 593-599.	0.9	11
176	Consistently Inconsistent? Bone Marrow Mononuclear Stem Cell Therapy Following Acute Myocardial Infarction. <i>Circulation Research</i> , 2016, 119, 404-406.	2.0	18
177	New Definition of Aging?. <i>Circulation Research</i> , 2016, 119, 774-775.	2.0	4
178	False Activations for ST-Segment Elevation Myocardial Infarction. <i>Interventional Cardiology Clinics</i> , 2016, 5, 451-469.	0.2	10
179	Come one, come all! the sooner the better!. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 88, 689-690.	0.7	0
180	Don't you forget about me! The 80s still matter!. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 689-690.	0.7	0

#	ARTICLE	IF	CITATIONS
181	“More may mean less” – the role for simulation-based medical education in the cardiac catheterization laboratory. <i>Catheterization and Cardiovascular Interventions</i> , 2016, 87, 389-390.	0.7	1
182	Eligibility and utilization of implantable cardioverter-defibrillators in a regional STEMI system. <i>Heart Rhythm</i> , 2016, 13, 538-546.	0.3	2
183	Unplanned Inpatient and Observation Rehospitalizations After Acute Myocardial Infarction. <i>Circulation</i> , 2016, 133, 493-501.	1.6	26
184	Impact of Hemoglobin A1c Levels on Residual Platelet Reactivity and Outcomes After Insertion of Coronary Drug-Eluting Stents (from the ADAPT-DES Study). <i>American Journal of Cardiology</i> , 2016, 117, 192-200.	0.7	16
185	Contemporary use of platelet function and pharmacogenomic testing among patients with acute myocardial infarction undergoing percutaneous coronary intervention in the United States. <i>American Heart Journal</i> , 2015, 170, 706-714.	1.2	5
186	Time to consider a <sc>STEMI</sc> sleepover?: Measuring the “value” of an in-house <sc>STEMI</sc> team. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 197-198.	0.7	0
187	Direct Transfer From the Referring Hospitals to the Catheterization Laboratory to Minimize Reperfusion Delays for Primary Percutaneous Coronary Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e002477.	1.4	18
188	Gender equity in <sc>STEMI</sc>: Not so simple!. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 85, 369-370.	0.7	4
189	Association of Discharge Aspirin Dose With Outcomes After Acute Myocardial Infarction. <i>Circulation</i> , 2015, 132, 174-181.	1.6	45
190	Fibrinolysis Use Among Patients Requiring Interhospital Transfer for ST-Segment Elevation Myocardial Infarction Care. <i>JAMA Internal Medicine</i> , 2015, 175, 207.	2.6	72
191	Is There an Ideal Level of Platelet P2Y12-Receptor Inhibition in Patients Undergoing Percutaneous Coronary Intervention?. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1978-1987.	1.1	31
192	Early Medication Nonadherence After Acute Myocardial Infarction. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2015, 8, 347-356.	0.9	55
193	Efficacy of a Device to Narrow the Coronary Sinus in Refractory Angina. <i>New England Journal of Medicine</i> , 2015, 372, 519-527.	13.9	205
194	Increasing Percutaneous Coronary Interventions for ST-Segment Elevation Myocardial Infarction in the United States. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 139-146.	1.1	59
195	Bone Marrow Characteristics Associated With Changes in Infarct Size After STEMI. <i>Circulation Research</i> , 2015, 116, 99-107.	2.0	65
196	Cluster-Randomized Clinical Trial Examining the Impact of Platelet Function Testing on Practice. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, e001712.	1.4	16
197	Cardiac Arrest. <i>Journal of the American College of Cardiology</i> , 2015, 66, 62-73.	1.2	156
198	Persistence with secondary prevention medications after acute myocardial infarction: Insights from the TRANSLATE-ACS study. <i>American Heart Journal</i> , 2015, 170, 62-69.	1.2	111

#	ARTICLE	IF	CITATIONS
199	Nationwide Analysis of Patients With ST-Segment Elevation Myocardial Infarction Transferred for Primary Percutaneous Intervention. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	49
200	Going Beyond the Hard Endpoints. <i>Journal of the American College of Cardiology</i> , 2015, 66, 2114-2115.	1.2	3
201	Repeat Cell Therapy for Refractory Angina. <i>Circulation: Cardiovascular Interventions</i> , 2015, 8, .	1.4	3
202	Incidence, Predictors, and Impact of Post-Discharge Bleeding After Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1036-1045.	1.2	344
203	Real-Time Decision Support to Guide Percutaneous Coronary Intervention Bleeding Avoidance Strategies Effectively Changes Practice Patterns. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2014, 7, 960-967.	0.9	17
204	One-Year Follow-up of Intracoronary Stem Cell Delivery on Left Ventricular Function Following ST-Elevation Myocardial Infarction. <i>JAMA - Journal of the American Medical Association</i> , 2014, 311, 301.	3.8	30
205	Safety and Efficacy of Ixmyelocel-T. <i>Circulation Research</i> , 2014, 115, 730-737.	2.0	56
206	Volume driven performance metrics in STEMI care: Does practice make perfect?. <i>Catheterization and Cardiovascular Interventions</i> , 2014, 84, 948-949.	0.7	0
207	Emergency Medical Services as a Strategy for Improving ST-Elevation Myocardial Infarction System Treatment Times. <i>Journal of Emergency Medicine</i> , 2014, 46, 355-362.	0.3	16
208	Treatment of refractory angina in patients not suitable for revascularization. <i>Nature Reviews Cardiology</i> , 2014, 11, 78-95.	6.1	116
209	Outcomes of Primary Percutaneous Coronary Intervention in ST-Segment Elevation Myocardial Infarction Patients With Previous Coronary Bypass Surgery. <i>JACC: Cardiovascular Interventions</i> , 2014, 7, 981-987.	1.1	19
210	Early Post-Discharge Bleeding and Antiplatelet Therapy Discontinuation Among Acute Myocardial Infarction Patients Treated With Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1700-1702.	1.2	10
211	Recruiting for Acute Myocardial Infarction Cell Therapy Trials: Challenges and Best Practices for the CCTR. <i>Clinical Researcher</i> , 2014, 28, 71-77.	0.5	2
212	Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. <i>Lancet, The</i> , 2013, 382, 1714-1722.	6.3	537
213	Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. <i>Lancet, The</i> , 2013, 382, 614-623.	6.3	740
214	A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: Design of the RENEW study. <i>American Heart Journal</i> , 2013, 165, 854-861.e2.	1.2	85
215	Regional systems of care for ST-elevation myocardial infarction: Do they save lives?. <i>American Heart Journal</i> , 2013, 166, 389-391.	1.2	2
216	Long-term survival in patients with refractory angina. <i>European Heart Journal</i> , 2013, 34, 2683-2688.	1.0	141

#	ARTICLE	IF	CITATIONS
217	Growth in Percutaneous Coronary Intervention Capacity Relative to Population and Disease Prevalence. <i>Journal of the American Heart Association</i> , 2013, 2, e000370.	1.6	72
218	Location, location, location! Is it important with cell delivery?. <i>Catheterization and Cardiovascular Interventions</i> , 2013, 81, 978-979.	0.7	3
219	Has the Time Come for a National Cardiovascular Emergency Care System?. <i>Circulation</i> , 2012, 125, 2035-2044.	1.6	30
220	From Concept to Reality. <i>Circulation</i> , 2012, 126, 166-168.	1.6	22
221	Safety and efficacy of a pharmaco-invasive reperfusion strategy in rural ST-elevation myocardial infarction patients with expected delays due to long-distance transfers. <i>European Heart Journal</i> , 2012, 33, 1232-1240.	1.0	78
222	Bad kidneys are bad for the heart: But what can we do about it?. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 80, 358-360.	0.7	2
223	TCT-524 Does the Zwolle Percutaneous Coronary Intervention Risk Index Identify Low Risk ST-Elevation Myocardial Infarction Patients for Early Discharge?. <i>Journal of the American College of Cardiology</i> , 2012, 60, B151-B152.	1.2	1
224	How gold is the gold standard? How gold does it need to be?. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 1099-1100.	0.7	1
225	Primary PCI in the elderly: 75 may be the new 55!. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 57-58.	0.7	4
226	Causes of Delay and Associated Mortality in Patients Transferred With ST-Segmentâ€“Elevation Myocardial Infarction. <i>Circulation</i> , 2011, 124, 1636-1644.	1.6	118
227	Is it time to â€œRescueâ€•Rescue PCI?. <i>Catheterization and Cardiovascular Interventions</i> , 2011, 77, 605-607.	0.7	0
228	Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina. <i>Circulation Research</i> , 2011, 109, 428-436.	2.0	433
229	Therapeutic Hypothermia After Out-of-Hospital Cardiac Arrest. <i>Circulation</i> , 2011, 124, 206-214.	1.6	184
230	Skeletal myoblasts for myocardial regeneration in patients with congestive heart failure: where have all the answers gone?. <i>EuroIntervention</i> , 2011, 6, 789-793.	1.4	1
231	Pharmaco-invasive Strategies Expand Access to Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction. <i>Progress in Cardiovascular Diseases</i> , 2010, 53, 188-194.	1.6	2
232	Patients with coronary artery disease not amenable to traditional revascularization: Prevalence and 3â€“year mortality. <i>Catheterization and Cardiovascular Interventions</i> , 2010, 75, 886-891.	0.7	99
233	Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary Intervention. <i>American Heart Journal</i> , 2010, 160, 202-207.	1.2	23
234	More than one leg to stand on: A step forward in the management of critical limb ischemia. <i>Catheterization and Cardiovascular Interventions</i> , 2009, 74, 20-21.	0.7	3

#	ARTICLE	IF	CITATIONS
235	A new option for the "no-option" patient with refractory angina?. Catheterization and Cardiovascular Interventions, 2009, 74, 395-397.	0.7	6
236	Reperfusion options in ST-elevation myocardial infarction patients with expected delays. Current Cardiology Reports, 2008, 10, 415-423.	1.3	1
237	Clinical and research issues regarding chronic advanced coronary artery disease. American Heart Journal, 2008, 155, 418-434.	1.2	43
238	Clinical and research issues regarding chronic advanced coronary artery disease Part II: Trial design, outcomes, and regulatory issues. American Heart Journal, 2008, 155, 435-444.	1.2	48
239	Enhanced external counterpulsation improves systolic blood pressure in patients with refractory angina. American Heart Journal, 2008, 156, 1217-1222.	1.2	24
240	Response to Letter Regarding Article, "A Regional System to Provide Timely Access to Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction". Circulation, 2008, 117, .	1.6	0
241	Myocardial Fibrosis From Severe Carbon Monoxide Poisoning Detected by Cardiac Magnetic Resonance Imaging. Circulation, 2008, 118, 792-792.	1.6	23
242	Intramyocardial Transplantation of Autologous CD34 + Stem Cells for Intractable Angina. Circulation, 2007, 115, 3165-3172.	1.6	516
243	A Regional System to Provide Timely Access to Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction. Circulation, 2007, 116, 721-728.	1.6	438
244	Effects of Ad5FGF-4 in Patients With Angina. Journal of the American College of Cardiology, 2007, 50, 1038-1046.	1.2	210
245	ST-Segment Elevation Myocardial Infarction: Recommendations on Triage of Patients to Heart Attack Centers. Journal of the American College of Cardiology, 2006, 47, 1339-1345.	1.2	92
246	Contemporary challenges in the management of acute myocardial infarction: ST-elevation myocardial infarction guidelines and the real world. American Heart Journal, 2006, 151, S11-S16.	1.2	9
247	Regional Transfer Programs for Primary Percutaneous Coronary Intervention. Critical Pathways in Cardiology, 2006, 5, 147-152.	0.2	0
248	Acute coronary syndromes in patients with renal disease: What are the issues?. Current Cardiology Reports, 2006, 8, 296-300.	1.3	2
249	Cardiovascular Manifestations of Moderate to Severe Carbon Monoxide Poisoning. Journal of the American College of Cardiology, 2005, 45, 1513-1516.	1.2	279
250	Design of a standardized system for transfer of patients with ST-elevation myocardial infarction for percutaneous coronary intervention. American Heart Journal, 2005, 150, 373-384.	1.2	131